Analysts Set Alto Neuroscience, Inc. (NYSE:ANRO) Target Price at $16.75

Shares of Alto Neuroscience, Inc. (NYSE:ANRO) have been assigned a consensus recommendation of “Moderate Buy” from the six analysts that are covering the company, MarketBeat Ratings reports. Three analysts have rated the stock with a hold rating and three have issued a buy rating on the company. The average 1-year price target among brokers that have issued a report on the stock in the last year is $16.75.

Separately, William Blair restated an “outperform” rating on shares of Alto Neuroscience in a report on Friday, March 21st.

Institutional Inflows and Outflows

Several hedge funds have recently bought and sold shares of the company. Wells Fargo & Company MN increased its stake in shares of Alto Neuroscience by 40.0% during the 4th quarter. Wells Fargo & Company MN now owns 10,989 shares of the company’s stock worth $46,000 after purchasing an additional 3,139 shares during the last quarter. Deutsche Bank AG raised its position in shares of Alto Neuroscience by 31.3% in the fourth quarter. Deutsche Bank AG now owns 15,210 shares of the company’s stock valued at $64,000 after purchasing an additional 3,629 shares during the period. BNP Paribas Financial Markets lifted its stake in shares of Alto Neuroscience by 619.2% in the third quarter. BNP Paribas Financial Markets now owns 4,315 shares of the company’s stock worth $49,000 after buying an additional 3,715 shares during the last quarter. Rhumbline Advisers grew its stake in Alto Neuroscience by 24.4% in the 4th quarter. Rhumbline Advisers now owns 25,556 shares of the company’s stock valued at $108,000 after buying an additional 5,008 shares during the last quarter. Finally, Philadelphia Financial Management of San Francisco LLC raised its holdings in Alto Neuroscience by 1.5% in the 3rd quarter. Philadelphia Financial Management of San Francisco LLC now owns 449,952 shares of the company’s stock worth $5,147,000 after acquiring an additional 6,663 shares during the period.

Alto Neuroscience Stock Performance

Shares of ANRO stock opened at $2.56 on Friday. The business has a 50 day simple moving average of $3.56 and a 200 day simple moving average of $5.90. The company has a debt-to-equity ratio of 0.05, a current ratio of 13.10 and a quick ratio of 13.09. The firm has a market capitalization of $69.04 million and a price-to-earnings ratio of -1.01. Alto Neuroscience has a 12-month low of $2.53 and a 12-month high of $18.35.

Alto Neuroscience (NYSE:ANRO) last released its quarterly earnings results on Thursday, March 20th. The company reported ($0.56) EPS for the quarter, topping analysts’ consensus estimates of ($0.65) by $0.09. On average, equities research analysts anticipate that Alto Neuroscience will post -2.54 EPS for the current year.

About Alto Neuroscience

Alto Neuroscience, Inc operates as a clinical-stage biopharmaceutical company in the United States. Its product pipeline comprising ALTO-100, which is in phase 2b clinical trial for the treatment of patients with major depressive disorder (MDD); and which is in phase 2a clinical trial for the treatment of post-traumatic stress disorder.